Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells
about
Targeting DNA Replication Stress for Cancer TherapyImproving the efficacy of chemoradiation with targeted agentsNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionA perspective on anti-EGFR therapies targeting triple-negative breast cancerA phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportEffect of BRCA1 on epidermal growth factor receptor in ovarian cancer.Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.Development of synthetic lethality anticancer therapeutics.Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repairRegulators of homologous recombination repair as novel targets for cancer treatment.Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Autoimmune response to PARP and BRCA1/BRCA2 in cancerAdvances in small-molecule drug discovery for triple-negative breast cancer.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.PARP1 Inhibitors: antitumor drug design.DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cellsPhosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletionComparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesThe potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.PARP inhibitors in cancer therapy: an update.The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.Discussion of PARP inhibitors in cancer therapy.Deciphering the insights of poly(ADP-ribosylation) in tumor progression.Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma.Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies.Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.DNA-PkCS expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgery.Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.
P2860
Q26739923-420ABE09-0837-4204-A042-39E841DC43B6Q26850193-4325F139-FFDD-4ADE-A358-5292E1E31947Q26851765-FD97320A-0748-4F6D-B7E0-8F06477F3F4FQ28069867-4D94ED2E-9AA9-4471-BB55-A3E5082DA473Q33415790-0ED42247-EEE5-4A87-BBF1-ED6948DC5590Q33643669-F6C639CE-4013-463A-B7B2-B16633025B0BQ33685138-98B505D3-5394-4FFE-BBC3-4491A70775DDQ34380368-62F62546-D86D-4197-9E53-FDF829093E90Q34580487-0946C588-5AC2-4193-8CE7-A124E07316B3Q34777845-C2731823-D615-4639-B17B-674ADAF26F9AQ35200273-FECC0480-6C61-4420-8291-9977BF4469C9Q35274741-66F6BF78-A928-4581-855B-E893692F7281Q35793861-4082AE6C-0D8A-4680-A8F7-5E055F0BC568Q35818491-6063B1B1-D1C0-4C47-A215-0C0D268C6836Q35895214-2993222D-9389-4E01-B494-C5668DC0DF98Q36175159-695DB7AA-CEFA-44BC-87BE-16435C400FB2Q36413681-058C5933-9047-4ADB-AB0D-B811371996E3Q36583169-E311D48D-E82D-4502-9A1B-53FFCF8B6862Q36854062-18B367FA-240E-4F10-BC7F-8432FA9916E8Q36879506-7F642565-CF26-4A6A-AEE5-6C41A1F0EC88Q36962531-78658F53-3727-41D6-882C-52B09E130AB3Q37109827-7E294DEF-BFF6-42D7-84DA-8896AE9E048DQ37142812-26E2D63D-1602-4059-9EA2-E5CF2E9087E5Q37269217-9902B11E-16D4-49CC-B66D-19A4F6E98600Q37304764-15092E23-FC79-4EDA-B14E-B3755CBB0D80Q38078993-95A3E98F-A52C-4A13-BCE1-D6DE87D27D41Q38142158-500B0638-1738-42C8-A69D-7CC41F6A8553Q38163013-B8A5D783-6B51-4214-B1EE-7BD595B9DD34Q38325685-DD2BE481-2BE8-478C-BCE5-C610B943D435Q38541699-CD2026C8-946A-48E6-913A-EFED48C489DDQ38683171-CF20C703-DA3E-4551-BC8A-7070804D5A88Q38718745-AC276FC9-7030-42D3-88D6-C9A6B6FC2486Q39468007-724991BB-DD38-440F-B853-FCF0E1361DE5Q40456709-E6212DF2-DDEB-4E99-8075-BD4CCB66B1CDQ41276800-CF59C172-C4E3-457A-B018-36A5AF7BB154Q42513590-4210C937-D317-4217-8FCE-7F8AD5148011Q43627971-616F6E51-00F5-4B8E-A833-423B96E030EBQ47122646-08654B4E-6227-4DAC-AD07-0AD8DC1C7C0AQ55100687-D1CE45CD-1186-4717-BD4B-DB7F77922F88
P2860
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Synthetic lethal interactions ...... e negative breast cancer cells
@ast
Synthetic lethal interactions ...... e negative breast cancer cells
@en
Synthetic lethal interactions ...... e negative breast cancer cells
@nl
type
label
Synthetic lethal interactions ...... e negative breast cancer cells
@ast
Synthetic lethal interactions ...... e negative breast cancer cells
@en
Synthetic lethal interactions ...... e negative breast cancer cells
@nl
prefLabel
Synthetic lethal interactions ...... e negative breast cancer cells
@ast
Synthetic lethal interactions ...... e negative breast cancer cells
@en
Synthetic lethal interactions ...... e negative breast cancer cells
@nl
P2093
P2860
P1433
P1476
Synthetic lethal interactions ...... e negative breast cancer cells
@en
P2093
Eddy S Yang
Jennifer A Stanley
Somaira Nowsheen
Tiffiny Cooper
P2860
P304
P356
10.1371/JOURNAL.PONE.0046614
P407
P577
2012-10-11T00:00:00Z